BOSTON - Jean Christophe, a director at Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), disposed of 10,000 shares of common stock on November 17, 2026, generating proceeds of $1,096,550, according to a regulatory filing. The shares were sold in multiple transactions at prices spanning $106.81 to $115.00 per share.
The sale was executed in three blocks: 5,000 shares at $106.81, 2,500 shares at $110.00, and 2,500 shares at $115.00. The transactions occurred as RYTM stock trades at $119.04, close to its 52-week high of $122.20, following a 36.5% gain over the past six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, placing it among stocks on the Most Overvalued list.
Prior to the sales, Mr. Christophe acquired 10,000 shares of common stock through the exercise of stock options at $34.89 per share, totaling $348,900. These options had fully vested upon the earlier of one year from the grant date or the company’s next annual meeting of stockholders.
All reported transactions, including the option exercise and subsequent sales, were carried out pursuant to a Rule 10b5-1 trading plan. This plan was adopted by Mr. Christophe on August 18, 2026. Investors seeking deeper insights can access a comprehensive Pro Research Report on RYTM, one of over 1,400 US equities covered with expert analysis and actionable intelligence.
In other recent news, Rhythm Pharmaceuticals reported third-quarter 2026 results, exceeding Wall Street expectations with revenue of $92.1 million. This figure surpassed both the FactSet consensus of $85.6 million and Oppenheimer’s estimate of $81.8 million. The company also posted an adjusted loss of $0.61 per share, which was smaller than analysts’ projected loss of $0.71. RBC Capital maintained its Outperform rating on the stock, while Citizens raised its price target to $166, citing strong early performance of the Imcivree launch for hypothalamic obesity. The launch generated over 700 start forms from more than 500 prescribers in the two quarters following approval. Despite the positive earnings and revenue results, shares fell in premarket trading as investors considered the company’s spending plans and financing strategies. Oppenheimer reiterated a Perform rating on the stock following the earnings announcement. These developments highlight the ongoing interest and scrutiny from investors and analysts regarding Rhythm Pharmaceuticals’ financial performance and strategic direction.